Form 4: Mirum Pharmaceuticals Executive Lara Longpre Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Lara Longpre, Chief Development Officer of Mirum Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On September 10, 2019, Lara Longpre acquired 965 shares of Mirum Pharmaceuticals common stock at a price of $10.64 per share.
- On January 9, 2023, Lara Longpre sold 1,003 shares of common stock at a price of $20.6223 per share.
- The sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the reported transactions, Longpre directly owns 104,369 shares of Mirum Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document reports routine stock transactions by an executive to cover tax obligations, which is a common practice.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in stock transactions by company insiders. This filing indicates routine activity related to executive compensation and tax obligations.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 09/10/2019 | Lara Longpre acquired 965 shares of Mirum Pharmaceuticals common stock. |
| 01/09/2023 | Lara Longpre sold 1,003 shares of common stock to cover tax withholding obligations. |
| 03/18/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.